Pharmaceutical Grade Calcium Lactate

In high-load calcium supplement tablets, the choice of calcium lactate pentahydrate rather than calcium carbonate is driven by a formulation-mass problem that becomes acute at a label claim of 500 mg elemental calcium per tablet. The USP-NF calcium lactate pentahydrate monograph defines active content at 98.0%–101.0% on the dried basis, and the theoretical calcium content of the pentahydrate is 13.0 wt% based on Ca 40.08 g/mol / 308.3 g/mol; delivering 500 mg elemental calcium therefore requires approximately 3.85 g of active substance in a single unit. If a direct-compression formulation contains microcrystalline cellulose at 15 wt%, croscarmellose sodium at 2 wt%, and magnesium stearate at 0.5 wt%, the active fraction is 82.5 wt% and the finished tablet mass reaches approximately 4.67 g. This is outside conventional swallowable tablet geometry unless the development brief explicitly accepts a large oval or caplet format and selects excipients for brittle-lattice compaction rather than plastic deformation. The direct-compression blend is equilibrated at 40–55% RH for not less than 24 h before compression to stabilize moisture distribution between the hydrated salt and cellulosic excipients. On an instrumented rotary tablet press with pre-compression, capping and lamination are observed when hardness exceeds 10–12 kp at high turret speed, so the compression profile is normally set with an initial pre-compression force of 2–5 kN followed by a main compression force adjusted to produce a tablet hardness of 7–10 kp. The downstream production process for oral solid dosage forms is governed by 21 CFR 210/211 cGMP, with release testing under USP <905> uniformity of dosage units, USP <711> dissolution in 0.1 N hydrochloric acid at 37°C for immediate-release tablets, and elemental impurity control according to ICH Q3D Table A.1.1 oral permitted daily exposure limits. The terminal product type is an immediate-release oral calcium supplement tablet intended for adult and geriatric populations, packaged in aluminum/PVC blister formats to limit moisture gain during distribution.

What Limits Calcium Lactate Loading in Aqueous Oral Suspensions?

Calcium lactate pentahydrate is described in the British Pharmacopoeia solubility table as soluble in 20 parts of water, which corresponds to a practical saturated solution concentration near 50 mg/ml at ambient temperature. This solubility is sufficient for lower-dose pediatric liquids delivering 100–150 mg elemental calcium per 5 ml dose, but it is insufficient for a fully dissolved adult dose of 500 mg elemental calcium in a single tablespoon without either a suspension strategy or a higher pH that may destabilize preservative systems. The formulation addition ratio is therefore determined by the decision to dissolve or suspend: fully dissolved systems typically employ 2–5 wt% calcium lactate pentahydrate in a sorbitol/glycerin syrup base, while higher-dose oral suspensions contain 10–20 wt% active substance dispersed with xanthan gum or microcrystalline cellulose/sodium carboxymethylcellulose. The downstream liquid manufacturing process uses a jacketed stainless-steel mixing vessel at 50–60°C to dissolve the lactate salt, followed by cooling to 25°C before addition of heat-labile flavor components, then high-shear homogenization of the suspending agents, vacuum de-aeration at −0.6 to −0.8 bar, and filling into amber polyethylene terephthalate bottles on a piston-filling line. The terminal dosage form is an oral syrup or oral suspension with pH adjusted to 5.5–6.5 using citric acid or sodium citrate; preservative efficacy is verified according to USP <51>, microbial limits follow USP <61>/<62>, and stability is validated under ICH Q1A(R2) zone II conditions. Orthophosphate buffer salts must be avoided in the aqueous vehicle because calcium phosphate precipitation occurs above approximately pH 4.0, producing visible sedimentation and loss of available calcium.

Effervescent calcium lactate granulation introduces a process conflict between the bound water of the pentahydrate crystal and the residual free-moisture threshold demanded by an acid-base effervescent couple. A formulation targeting 250 mg elemental calcium per tablet contains 1.92 g calcium lactate pentahydrate, equivalent to 250 mg elemental calcium at 13.0 wt%, combined with citric acid anhydrous and sodium bicarbonate in a ratio that exceeds simple stoichiometric balance to ensure brisk liquid-phase gas release. The production sequence on a fluid-bed granulator begins with pre-blending the acid and lactate salt, spraying a non-aqueous binder solution of polyethylene glycol 6000 in isopropanol at an inlet air temperature of 35–45°C, and drying to a final granule moisture below 0.3 wt% as measured by Karl Fischer titration. The dried granules are sieved to 100–500 µm, blended with sodium bicarbonate and lubricant in a humidity-controlled suite maintained below 20% RH, and compressed on a rotary tablet press with cooled tooling to prevent surface pitting from localized water release. The compliance test for the terminal effervescent tablet is USP <701> disintegration using 200 ml purified water at 15–25°C, with complete disintegration typically not exceeding 5 minutes; the finished product is an oral effervescent tablet or granule filled into aluminum-laminate tubes with desiccant. Water-based granulation is incompatible with this process because the pentahydrate may partially dissolve and recrystallize as a denser, poorly compressible mass while initiating premature carbon dioxide loss. The following formulation ranges are used for initial development trials; mass fractions must be normalized per batch because upper and lower limits do not represent a single fixed formula.

Chewable Tablet Binder Compatibility and the Moisture Uptake Boundary

Chewable calcium lactate tablets differ from swallowed solid dosage forms in that the active salt remains in the mouth long enough for lactic acid bitterness to emerge, so sensory masking rather than chemical stability determines the acceptable addition ratio. A chewable unit delivering 250 mg elemental calcium uses 1.92 g calcium lactate pentahydrate, which is approximately 55–65 wt% of a 3.0–3.5 g tablet; reducing active below 50 wt% requires a corresponding increase in compressible sugar or sorbitol, and sorbitol intake above 20 g/day introduces a known laxation risk. The downstream process is wet granulation with a low-viscosity polyvinylpyrrolidone binder dissolved in purified water, followed by tray drying at 45–55°C because higher bed temperatures darken reducing sugars and reduce flavor intensity; granule sizing through a 1000 µm oscillating screen, lubrication with 1–1.5 wt% stearic acid, and final compression to a hardness of 5–8 kp produce a tablet that crumbles under chewing but resists breakage in bulk packaging. The terminal product type is a chewable calcium supplement tablet, quality-controlled under 21 CFR 210/211, USP <905> uniformity of dosage units, and USP <61>/<62> microbial limits; because the tablet is labeled chewable, USP <2040> disintegration testing may be omitted if the product meets the compendial definition for a chewable formulation. The operational boundary is that relative humidity above 60% RH during mixing and granulation causes calcium lactate to soften and adhere to granulator screens, increasing screen blinding and reducing granule yield.

Low-Humidity Stick-Pack Filling for Calcium Lactate Oral Powders

Single-dose oral powder sachets containing calcium lactate pentahydrate are used where the target daily calcium dose exceeds what can be swallowed as a tablet, or where elderly patients require a dispersible dose that can be poured directly into water or soft food. A 1.0 g stick-pack formulation can deliver 130 mg elemental calcium if the active fill is 100% calcium lactate pentahydrate, but such a formulation is prone to segregation and poor hopper flow; commercial blends therefore dilute the active to 70–85 wt% with maltodextrin, citric acid anhydrous, xylitol, and silicon dioxide. The downstream process begins with electronic batch weighing and low-shear tumble blending at 15–25% RH, followed by vacuum transfer into a stick-pack machine with auger or volumetric dosing; because calcium lactate granules are irregular and hygroscopic, fill-weight control is maintained only when ambient dew point does not exceed 5°C. The stick-pack film structure for long-term bulk retention is typically PET12/Al7/PE40 to minimize moisture vapor transmission, and filled sachets are tested for seal integrity at 3–5 N/15 mm using ASTM F88/F88M-21. The terminal product is an oral powder for solution or suspension, reconstituted in 150–200 ml purified water before administration, with active quality governed by the USP-NF calcium lactate pentahydrate monograph, elemental impurity limits under ICH Q3D Table A.1.1, and microbial limits under USP <61>/<62>. Published data for specific stick-pack fill tolerances with calcium lactate pentahydrate is limited; site qualification should use a surrogate granulation matching the target bulk density and particle-size distribution before committing to full-scale filling.

When Roller Compaction Is Preferred over Direct Compression for Hard Capsule Blends

Hard shell capsules present a filling constraint that direct-compression powders often fail because the bulk density of crystallized calcium lactate pentahydrate is too low for size 00 capsules at a 250 mg elemental calcium dose. Roller compaction is therefore selected to increase bulk density from approximately 0.45–0.55 g/ml to 0.65–0.75 g/ml and to improve flow through an automatic capsule-filling machine. A capsule formulation delivering 125 mg elemental calcium per capsule contains 960 mg calcium lactate pentahydrate, which is 60–70 wt% of a 1.4 g fill weight; the remainder comprises microcrystalline cellulose, crospovidone, and 0.5 wt% sodium stearyl fumarate. The production route is dry granulation on a roller compactor with a roll pressure of 2–8 kN/cm roll width and a gap of 1.0–2.0 mm, followed by milling through a 1000 µm screen and lubrication in a low-shear bin blender. The terminal dosage form is a two-piece hard gelatin or hydroxypropyl methylcellulose capsule that must satisfy USP <711> dissolution in 0.1 N hydrochloric acid at 37°C and USP <905> uniformity of dosage units; capsule shell moisture exchange is controlled under ICH Q1A(R2) stability protocols with aluminum blister packaging. If relative humidity exceeds 50% RH during roller compaction, the fines can stick to the rolls and produce ribbons with density fluctuations, leading to fill-weight variation in the capsule hopper and inconsistent dissolution due to non-uniform tablet-like plug formation inside the capsule shell.